When overgrowth bumps into cancer: The PTEN-Opathies

American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

Volumn 163, Issue 2, 2013, Pages 114-121

  Mester, Jessica ^a   Eng, Charis ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NATIONAL ACADEMIES OF SCIENCES   (United States)

Author keywords

AKT; Cowden syndrome; MTOR; PI3K; PIK3CA; PTEN

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ARTICLE; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL FEATURE; COLON CANCER; COWDEN SYNDROME; DEPHOSPHORYLATION; ENDOMETRIUM CANCER; FAMILY HISTORY; GENE MUTATION; GERM LINE; HAMARTOMA; HUMAN; KIDNEY CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; PEUTZ JEGHERS SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; PTEN HAMARTOMA TUMOR SYNDROME; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

EID: 85027931809     PISSN: 15524868     EISSN: 15524876     Source Type: Journal    
DOI: 10.1002/ajmg.c.31364     Document Type: Article

References (67)

1. Aicher LD, Campbell JS, Yeung RS. 2001. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis. J Biol Chem 276:21017-21021.
2. Bannayan GA. 1971. Lipomatosis, angiomatosis, and macrencephalia. A previously undescribed congenital syndrome. Arch Pathol 92:1-5.
3. Biesecker L. 2006. The challenges of Proteus syndrome: Diagnosis and management. Eur J Hum Genet 14:1151-1157.
4. Biesecker LG, Rosenberg MJ, Vacha S, Turner JT, Cohen MM. 2001. PTEN mutations and proteus syndrome. Lancet 358:2079-2080.
5. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. 2013. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet DOI: 10.1016/S0140-6736(12)61767-X [Epub ahead of print].
6. Brockmann K, Happle R, Oeffner F, Konig A. 2008. Monozygotic twins discordant for Proteus syndrome. Am J Med Genet Part A 146A:2122-2125.
7. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, Eng C. 2005. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42:318-321.
8. Buxbaum JD, Cai G, Chaste P, Nygren G, Goldsmith J, Reichert J, Anckarsater H, Rastam M, Smith CJ, Silverman JM, Hollander E, Leboyer M, Gillberg C, Verloes A, Betancur C. 2007. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet Part B 144B:484-491.
9. Crino PB, Nathanson KL, Henske EP. 2006. The tuberous sclerosis complex. N Engl J Med 355:1345-1356.
10. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: A play in three Akts. Genes Dev 13:2905-2927.
11. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. 1998. Pten is essential for embryonic development and tumour suppression. Nat Genet 19:348-355.
12. Dumont FJ, Su Q. 1996. Mechanism of action of the immunosuppressant rapamycin. Life Sci 58:373-395.
13. Ekinci S, Karnak I, Balci S, Tanyel FC, Buyukpamukcu N. 2006. Bannayan-Riley-Ruvalcaba syndrome from the point of view of the pediatric surgeon. Eur J Pediatr Surg 16:209-213.
14. Eng C. 2003. PTEN: One gene, many syndromes. ??? 22:183-198.
15. Eng C, Murday V, Seal S, Mohammed S, Hodgson SV, Chaudary MA, Fentiman IS, Ponder BA, Eeles RA. 1994. Cowden syndrome and Lhermitte-Duclos disease in a family: A single genetic syndrome with pleiotropy? J Med Genet 31:458-461.
16. Furnari FB, Lin H, Huang HS, Cavenee WK. 1997. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 94:12479-12484.
17. Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA. 1992. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 44:307-314.
18. Greene AK, Orbach DB. 2011. Management of arteriovenous malformations. Clin Plast Surg 38:95-106.
19. Gu J, Tamura M, Yamada KM. 1998. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 143:1375-1383.
20. He X, Ni Y, Wang Y, Romigh T, Eng C. 2011. Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. Hum Mol Genet 20:80-89.
21. Kirk EP, Smith JM, Field M, Marshall GM, Marsh DJ. 2004. Diagnosis of Proteus syndrome was correct. Am J Med Genet Part A 130A:214-215; author reply 216-217.
22. Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. 2013. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology DOI: 101212/WNL0b013e3182815428 [Epub ahead of print].
23. Kurek KC, Howard E, Tennant LB, Upton J, Alomari AI, Burrows PE, Chalache K, Harris DJ, Trenor CC III, Eng C, Fishman SJ, Mulliken JB, Perez-Atayde AR, Kozakewich HP. 2012. PTEN hamartoma of soft tissue: A distinctive lesion in PTEN syndromes. Am J Surg Pathol 36:671-687.
24. Kurtz JE, Ray-Coquard I. 2012. PI3 kinase inhibitors in the clinic: An update. Anticancer Res 32:2463-2470.
25. Lachlan KL, Lucassen AM, Bunyan D, Temple IK. 2007. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: Results of a clinical study of PTEN mutation carriers. J Med Genet 44:579-585.
26. Li DM, Sun H. 1997. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57:2124-2129.
27. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
28. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67.
29. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG. 2011. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 365:611-619.
30. Lloyd KM II, Dennis M. 1963. Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 58:136-142.
31. Lobo GP, Waite KA, Planchon SM, Romigh T, Nassif NT, Eng C. 2009. Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function. Hum Mol Genet 18:2851-2862.
32. Lok C, Viseux V, Avril MF, Richard MA, Gondry-Jouet C, Deramond H, Desfossez-Tribout C, Courtade S, Delaunay M, Piette F, Legars D, Dreno B, Saiag P, Longy M, Lorette G, Laroche L, Caux F. 2005. Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) 84:129-136.
33. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 273:13375-13378.
34. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151-162.
35. Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. 1997. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16:333-334.
36. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboue B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C, et al. 1998. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7:507-515.
37. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, Bodurtha J, Crowe C, Curtis MA, Dasouki M, Dunn T, Feit H, Geraghty MT, Graham JM Jr, Hodgson SV, Hunter A, Korf BR, Manchester D, Miesfeldt S, Murday VA, Nathanson KL, Parisi M, Pober B, Romano C, Eng C, et al. 1999. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 8:1461-1472.
38. Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM. 2008. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 5:357-361.
39. Marsh DJ, Trahair TN, Kirk EP. 2011. Mutant AKT1 in Proteus syndrome. N Engl J Med 365:2141-2142; author reply 2142.
40. McBride KL, Varga EA, Pastore MT, Prior TW, Manickam K, Atkin JF, Herman GE. 2010. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res 3:137-141.
41. Mester JL, Tilot AK, Rybicki LA, Frazier TW II, Eng C. 2011. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet 19:763-768.
42. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. 1997. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94:9052-9057.
43. Nelen MR, Padberg GW, Peeters EA, Lin AY, van den Helm B, Frants RR, Coulon V, Goldstein AM, van Reen MM, Easton DF, Eeles RA, Hodgsen S, Mulvihill JJ, Murday VA, Tucker MA, Mariman EC, Starink TM, Ponder BA, Ropers HH, Kremer H, Longy M, Eng C. 1996. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 13:114-116.
44. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. 2001. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314-10319.
45. Orloff MS, Eng C. 2008. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 27:5387-5397.
46. Orloff MS, He X, Peterson C, Chen F, Chen JL, Mester JL, Eng C. 2013. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet 92:76-80.
47. Padberg GW, Schot JD, Vielvoye GJ, Bots GT, de Beer FC. 1991. Lhermitte-Duclos disease and Cowden disease: A single phakomatosis. Ann Neurol 29:517-523.
48. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 98:10320-10325.
49. Risinger JI, Hayes AK, Berchuck A, Barrett JC. 1997. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57:4736-4738.
50. Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. 2000. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60:3504-3513.
51. Shen-Li H, Koujak S, Szablocs M, Parsons R. 2010. Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice. Cancer Biol Ther 10:1194-1200.
52. Smith JM, Kirk EP, Theodosopoulos G, Marshall GM, Walker J, Rogers M, Field M, Brereton JJ, Marsh DJ. 2002. Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet 39:937-940.
53. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39.
54. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362.
55. Tan WH, Baris HN, Burrows PE, Robson CD, Alomari AI, Mulliken JB, Fishman SJ, Irons MB. 2007. The spectrum of vascular anomalies in patients with PTEN mutations: Implications for diagnosis and management. J Med Genet 44:594-602.
56. Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, Milas K, Pederson H, Remzi B, Orloff MS, Eng C. 2011. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 88:42-56.
57. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. 2012. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400-407.
58. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. 2002. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99:13571-13576.
59. Turnbull MM, Humeniuk V, Stein B, Suthers GK. 2005. Arteriovenous malformations in Cowden syndrome. J Med Genet 42:e50.
60. Varga EA, Pastore M, Prior T, Herman GE, McBride KL. 2009. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med 11:111-117.
61. Weary PE, Gorlin RJ, Gentry WC Jr, Comer JE, Greer KE. 1972. Multiple hamartoma syndrome (Cowden's disease). Arch Dermatol 106:682-690.
62. Wei C, Amos CI, Zhang N, Wang X, Rashid A, Walker CL, Behringer RR, Frazier ML. 2008. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res 14:1167-1171.
63. Weng LP, Smith WM, Dahia PL, Ziebold U, Gil E, Lees JA, Eng C. 1999. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 59:5808-5814.
64. Weng LP, Brown JL, Eng C. 2001. PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10:599-604.
65. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D. 2003. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13:2004-2008.
66. Yalon M, Ben-Sira L, Constantini S, Toren A. 2011. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Childs Nerv Syst 27:179-181.
67. Zhou X, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, Parisi M, Winter RM, Eng C. 2001. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 358:210-211.